Abstracts tagged "interferon"

Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Matthew Martin¹, Erik Wilker¹, Diana Gikunju¹, Usha Narayanan¹, Unnati Pandya¹, Vijetha Prakash¹, Ashley Edwards¹, Sameer Kawatkar¹, Tenghui Chen¹, Ragunath Chandran¹, Sai Sunder¹, Sumathi Biradar¹, Joerg Distler², Alexandra Joseph¹, Stephanos Ioannidis¹ and Bhavatarini Vangamudi¹, ¹Exo Therapeutics, Cambridge, MA, ²Exo Therapeutics, Düsseldorf, Germany
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
Abstract Number: 0092 • ACR Convergence 2024
A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis
Hulya Bukulmez¹, Adrienne Dennis², kristine Highland³ and Steven N. Emancipator⁴, ¹MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, ²MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH
Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
Abstract Number: 1426 • ACR Convergence 2024
Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis
Alejandro Gomez-Gomez¹, yolanda Guillen², Paloma Vela Casasempere³, María Paula álvarez Hernández⁴, Ignacio Brana Abascal⁵, Mónica Fernández Castro⁶, Maria López Lasanta¹, José María Pego-Reigosa⁷, Carlos Marras⁸, María García-Villanueva⁹, Francisco Blanco¹⁰, Patricia Carreira¹¹, Carolina Perez-Garcia¹², Íñigo Rúa-Figueroa¹³, Hugo F Avalos bogado¹, Natalia Boix Martí¹, Eric Kirkegaard-Biosca¹⁴, iago álvarez Sáez¹⁵, Nuria Palau¹⁶, Raül Tortosa¹⁶, Jesús Tornero Molina¹⁷, Antonio Fernandez Nebro¹⁸, Jaime Calvo-Alén¹⁹, Juan Cañete²⁰, Damiana Alvarez-Errico², Ernest Choy²¹, Holger Heyn²², Antonio Julia²³, Sara Marsal barril¹ and Jose Luis Andreu²⁴, and on behalf of SSAD and DocTIS consortia, ¹Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ²Imidomics, Inc, Barcelona, Spain, ³Hospital General Universitario de Alicante , Rheumatology, Alicante, Spain, ⁴Hospital universitario de la Princesa. IIS-Princesa, Rheumatology, Madrid, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain, ⁷Galicia Health Service (SERGAS), Vigo, Spain, ⁸Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁹Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁰Complejo Hospitalario Universitario de A Coruña , Rheumatology, A Coruña, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ¹⁴Hospital Universitari Vall d´Hebron, Ophtalmology, Barcelona, Spain, ¹⁵Hospital Universitari Vall d´Hebron, Maxillofacial Surgery, Barcelona, Spain, ¹⁶Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, ¹⁷Sociedad Española de Reumatologia, Rheumatology, Madrid, Spain, ¹⁸Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, ¹⁹Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ²⁰Hospital Clinic an IDIBAPS, Barcelona, Spain, ²¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²²Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, ²³Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: Primary Sjögren’s Syndrome (pSS) shares with SLE and RA features including their predominance in women, immunological characteristics and genetic risk background. Hence, to dissect…
Abstract Number: 1792 • ACR Convergence 2024
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Preetha Balasubramanian², Zurong Wan², Juan Rodriguez Alcazar², Marina Lima Silva Santos², Lynnette Walters³, Jeanine Baisch², Karen Onel⁴, Tracey Wright⁵, Virginia Pascual⁶ and Simone Caielli², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Scottish Rite Hospital for Children, Allen, TX, ⁴HSS, New York, NY, ⁵UT Southwestern, Plano, TX, ⁶Weill Cornell Medical College, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
Abstract Number: 2540 • ACR Convergence 2024
Characterizing the Functional Role of Type I Interferons in Inflammatory Arthritis
Mary Huang, Richard Bell, Toolika Singh and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation due to cellular infiltration and inflammatory mediators. Type I interferons (IFN) have…
Abstract Number: 0093 • ACR Convergence 2024
Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Benjamin Klein¹, Kelsey E. McNeely², Debbie Colesa², Yiqing Gao², Nguyen Thi Kim Nguyen², Johann Gudjonsson¹ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Michigan Medicine, Ann Arbor, MI
Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
Abstract Number: 1430 • ACR Convergence 2024
C57BL/6.NOD-Aec1Aec2 Mice Recapitulate Sjögren’s Serology Better Than NOD.B10Sn-H2b Models and JAK Inhibitor Treatment Improves Immunoglobulins and Salivary Gland Inflammation but Not Salivary Flow in Sjögren’s Mice
Sara McCoy¹ and Ilya Gurevic², ¹University of Wisconsin, Middleton, WI, ²University of Wisconsin, Madison
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease in which interferons (IFNs) are believed to play a major role/ JAK inhibitors (JAKinibs) block IFN…
Abstract Number: 1793 • ACR Convergence 2024
SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD
Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
Abstract Number: 2547 • ACR Convergence 2024
Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Vanessa Rodriguez¹ and Carla Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity…
Abstract Number: 0328 • ACR Convergence 2024
IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
Melissa Leeolou¹, Lorinda Chung², Kavita Sarin³ and david fiorentino⁴, ¹Stanford University School of Medicine, Redwood City, CA, ²Stanford University, Woodside, CA, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA
Background/Purpose: Type I interferon (IFN) plays a role in the pathogenesis of dermatomyositis (DM) and correlates with measures of disease activity. Melanoma differentiation-associated gene 5…
Abstract Number: 1497 • ACR Convergence 2024
Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus
Justin Smith¹, Laura Patricia Whittall Garcia², Dennisse Bonilla², Qixuan Li², Robert Terbrueggen³, Hemani Wijesuriya³, Ian Richards³, Aviva Jacobs³, Joan Wither², Dafna Gladman⁴ and Zahi Touma⁵, and DxTerity, ¹University of Toronto, Toronto, AB, Canada, ²University Health Network, Toronto, ON, Canada, ³DxTerity Diagnostics Inc., Torrance, CA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I interferons (IFN) are pivotal in the pathogenesis of SLE, with studies showing high IFN gene signature (IGS) status associated with certain organ…
Abstract Number: 1800 • ACR Convergence 2024
WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes
Bin Xu, Laura Cencer, Benjamin Klein, Shannon Loftus, Lam Tsoi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Our recent study uncovered a role for dysregulation of the Hippo signaling pathway in systemic lupus erythematosus (SLE) keratinocytes (KCs) driven by overexpression of…
Abstract Number: 2549 • ACR Convergence 2024
VISTA Deficiency Alters the Skin Immune Cell Composition and Confers Skin Sensitivity to UV Light
Zachary Peters¹, Lindsay Mendyka², Angelique Cortez¹, J'voughnn Blake¹, Alecia Roy¹, William Rigby³, Christopher Burns⁴, Randolph Noelle⁵ and Sladjana Skopelja-Gardner⁶, ¹Dartmouth College, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Dartmouth-Hitchcock, Norwich, VT, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Geisel School of Medicine at Dartmouth, Lebanon, ⁶Dartmouth Geisel School of Medicine, Lebanon, NH
Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of cutaneous lupus erythematosus (CLE) that is exacerbated by ultraviolet (UV) light.…
Abstract Number: 0617 • ACR Convergence 2024
Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation
Clément triaille¹, Neha Mohan Rao², Gillian Rice³, Luis Seabra⁴, Sutherland Fraser⁵, Vincent Bondet⁶, Darragh duffy⁶, Andrew Gennery⁷, Benjamin Fournier⁸, Brigitte Bader-Meunier⁹, Christopher Troedson¹⁰, Gavin CLeary¹¹, Helena Buso¹², Jacqueline Dalby-Payne¹³, Ranade Prajakta¹⁴, Katrien Jansen¹⁵, Lien De Somer¹⁶, Marie-Louise Fremond¹⁷, Pimple Pallavi¹⁴, Melanie Wong¹⁸, Russel Dale¹⁰, Carine Wouters¹⁶, PIERRE QUARTIER¹⁹, Raju Khubchandani²⁰ and Yanick Crow⁵, ¹Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, ²NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, ³Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, ⁴Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France, Paris, France, ⁵MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, Edinburgh, United Kingdom, ⁶Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, ⁷: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom, ⁸Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, France, ⁹Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ¹⁰T. Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, New South Wales, and University of Sydney, Australia, Sydney, Australia, ¹¹: Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, Liverpool, United Kingdom, ¹²Department of Medicine - DIMED, University of Padova, Padova, Italy, Padova, Italy, ¹³Specialty of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Australia, Sydney, Australia, ¹⁴NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, India, ¹⁵Division of Pediatric Neurology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁶Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁷Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, United Kingdom, ¹⁸Department of Allergy and Immunology, Children's Hospital at Westmead, Westmead, Australia, Westmead, Australia, ¹⁹Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, ²⁰SRCC Childrens Hospital, Mumbai, India
Background/Purpose: To report on the largest cohort of C1Q deficient (C1QDef ) patients; to investigate the activation of Type 1 interferon pathway in the blood…
Abstract Number: 1507 • ACR Convergence 2024
To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Tokunaga³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc., Tokyo, ³Japanese Red Cross Okayama Hospital, Okayama
Background/Purpose: IFN signatures are known to play an important role in the pathogenesis of systemic autoimmune diseases such as SLE. Recently, therapeutic agents targeting IFN…

1
2
3
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].